ImmunityBio stock
IBRXNASDAQImmunityBio, Inc., HealthcareISIN US45256X1037
37Score 37 out of 100, Weak
Price and trend
42 / 100
Price history
+195% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 24% below it.
Since January 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 35).
The price is 47% below its 52-week high. Largest decline in 11 years: 97% (July 2015 to June 2019).
Chart figures for advanced users
- SMA 50$8.63
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.97
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)35
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.98
- The lowest closing price of the last twelve months.
- Resistance$11.55
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- ImmunityBio, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $6.46B, is number 60 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $113.29M (up 668.3% year on year) and a loss of $351.4M.
- For fiscal 2026, analysts expect on average revenue of $226.56M (up 100%) and adjusted earnings per share of −$0.96.
Show more
- MEQIRI Score 37 out of 100 (Weak): rank 578 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 184.8% a year since 2020, Biotechnology median 19.4%.Growth 70
Weaknesses
- DilutionShare count up 140% since 2020.Capital allocation 18
- Volatile share priceVolatility 109% a year over the last 12 months.Stability 34
- Loss-makingLoss of $1.11B over the last 12 months.Fundamentals 17
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 38 to 37.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 121% on the twelve months before. Revenue has grown strongly since 2013, at around 55% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 99%, operating −226%, net −310%. Last 12 months: net −100%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 22 Feb 2027in 101 days
- Last reported
- 9 Nov 2026EPS reported −$0.17 (expected −$0.07)below expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 18.9% since 15 Oct 2026.
- Earnings per share
- −$0.960.0%
- Revenue
- $226.56M+0.4%
- Earnings per share
- −$0.11+18.9%
- Revenue
- $471.9M+3.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $5.04M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Simon Barry J.Sale
5 Oct 2026, Board
- Shares
- 25,000
- Price
- $10.75
- Value
- $268,760
- Cohen CherylSale
2 Oct 2026, Board
- Shares
- 81,056
- Price
- $10.50
- Value
- $851,088
- Cohen CherylSale
2 Jul 2026, Board
- Shares
- 131,210
- Price
- $9.50
- Value
- $1.25M
Show 5 more
- Selecky ChristobelSale
1 Jul 2026, Board
- Shares
- 159,478
- Price
- $9.02
- Value
- $1.44M
- Selecky ChristobelSale
30 Jun 2026, Board
- Shares
- 1,000
- Price
- $9.00
- Value
- $9,000
- Selecky ChristobelSale
29 Jun 2026, Board
- Shares
- 95,722
- Price
- $9.01
- Value
- $862,216
- Simon Barry J.Sale
24 Jun 2026, Board
- Shares
- 25,000
- Price
- $7.88
- Value
- $196,908
- Simon Barry J.Sale
4 Jun 2026, Board
- Shares
- 23,033
- Price
- $7.18
- Value
- $165,306
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at ImmunityBio
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Caris Life SciencesCAI $6.87B57
- Kodiak SciencesKOD $6.8B43
- Belite BioBLTE $6.76B45
- Arrowhead PharmaceuticalsARWR $6.66B30
- BioconBIOCON.NS $6.42B41
- Samsung Epis Holdings0126Z0.KS $6.4B41
- Ligand PharmaceuticalsLGND $6.33B60
- CG OncologyCGON $6.27B41
ETFs that hold ImmunityBio
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.56% | 0.35% | €1.25B |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.28% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.27% | 0.40% | €813.42M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.09% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.09% | 0.30% | €4.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.05% | 0.30% | €185.82M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.05% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 17 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.